Menten AI

Menten AI is a pioneering biotechnology company that combines quantum computing, artificial intelligence, and protein engineering to revolutionize drug discovery and design. Founded in 2018 by CEO Vikram Mulligan and leveraging research from the Baker Lab at the University of Washington, the company uses quantum-enhanced algorithms to solve complex protein folding and design problems that are computationally intractable for classical computers. Menten AI's platform enables the design of novel protein therapeutics, including peptides and small proteins, by exploring vast sequence spaces and optimizing for desired properties such as stability, specificity, and manufacturability. The company's quantum computing approach provides advantages in sampling complex conformational states and optimizing multi-objective design problems inherent in drug discovery. Menten AI has developed a pipeline of proprietary therapeutic candidates and offers computational design services to pharmaceutical partners. Their technology represents a convergence of quantum computing and biotechnology that could accelerate the development of new medicines for diseases including cancer, autoimmune disorders, and infectious diseases.